DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center
Standard
DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center. / Mikesch, Jan-Henrik; Kuhlmann, Mareike; Demant, Angela; Krug, Utz; Thoennissen, Gabriela B; Schmidt, Eva; Kessler, Torsten; Schliemann, Christoph; Pohlen, Michele; Mohr, Michael; Evers, Georg; Köhler, Gabriele; Wessling, Johannes; Mesters, Rolf; Müller-Tidow, Carsten; Berdel, Wolfgang E; Thoennissen, Nils H.
in: ANN HEMATOL, Jahrgang 92, Nr. 8, 08.2013, S. 1041-8.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - DexaBEAM versus ICE salvage regimen prior to autologous transplantation for relapsed or refractory aggressive peripheral T cell lymphoma: a retrospective evaluation of parallel patient cohorts of one center
AU - Mikesch, Jan-Henrik
AU - Kuhlmann, Mareike
AU - Demant, Angela
AU - Krug, Utz
AU - Thoennissen, Gabriela B
AU - Schmidt, Eva
AU - Kessler, Torsten
AU - Schliemann, Christoph
AU - Pohlen, Michele
AU - Mohr, Michael
AU - Evers, Georg
AU - Köhler, Gabriele
AU - Wessling, Johannes
AU - Mesters, Rolf
AU - Müller-Tidow, Carsten
AU - Berdel, Wolfgang E
AU - Thoennissen, Nils H
PY - 2013/8
Y1 - 2013/8
N2 - High-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) is considered standard in the treatment of patients with relapsed or refractory aggressive peripheral T cell lymphoma (PTCL). However, the optimal salvage regimen before ASCT has not yet been established. We retrospectively analyzed 31 patients with relapsed or refractory aggressive PTCL after anthracycline-based first-line chemotherapy who received either DexaBEAM (dexamethasone, carmustine, etoposide, cytarabine, and melphalan; n = 16) or ICE (ifosfamide, carboplatin, and etoposide; n = 15) regimen as first salvage chemotherapy followed by HDT/ASCT. The overall response rate (OR) was significantly higher for patients treated with DexaBEAM (69 %; 95 % confidence interval 46.0-91.5 %) as compared to the ICE group (20 %; 95 % confidence interval -0.2-40.2 %; P = 0.01), with higher complete response (CR; 38 %; 95 % confidence interval 13.8-61.2 %; vs. 7 %; 95 % confidence interval -6.0-19.6 %) as well as partial response (PR; 31 vs. 13 %) rate. Changing regimen due to failure of first salvage therapy, 12 patients initially receiving ICE still achieved an OR of 58 % (33 % CR, 25 % PR) with DexaBEAM as second salvage therapy, whereas in three patients receiving ICE after DexaBEAM failure, only one achieved an OR (1 PR). Median progression-free survival was significantly higher in the DexaBEAM group (6.4 vs. 2 months; P = 0.01). Major adverse event in both groups was myelosuppression with higher but tolerable treatment-related toxicity for patients in the DexaBEAM group. For all patients proceeding to HDT/ASCT, a 3-year overall survival was 50 %. Together, considering the limitations of the retrospective design of the evaluation and the small sample size, our data suggest that DexaBEAM salvage chemotherapy is superior to ICE for patients with relapsed or refractory aggressive PTCL for remission induction prior to autologous transplantation, with higher but manageable treatment-related toxicity.
AB - High-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT) is considered standard in the treatment of patients with relapsed or refractory aggressive peripheral T cell lymphoma (PTCL). However, the optimal salvage regimen before ASCT has not yet been established. We retrospectively analyzed 31 patients with relapsed or refractory aggressive PTCL after anthracycline-based first-line chemotherapy who received either DexaBEAM (dexamethasone, carmustine, etoposide, cytarabine, and melphalan; n = 16) or ICE (ifosfamide, carboplatin, and etoposide; n = 15) regimen as first salvage chemotherapy followed by HDT/ASCT. The overall response rate (OR) was significantly higher for patients treated with DexaBEAM (69 %; 95 % confidence interval 46.0-91.5 %) as compared to the ICE group (20 %; 95 % confidence interval -0.2-40.2 %; P = 0.01), with higher complete response (CR; 38 %; 95 % confidence interval 13.8-61.2 %; vs. 7 %; 95 % confidence interval -6.0-19.6 %) as well as partial response (PR; 31 vs. 13 %) rate. Changing regimen due to failure of first salvage therapy, 12 patients initially receiving ICE still achieved an OR of 58 % (33 % CR, 25 % PR) with DexaBEAM as second salvage therapy, whereas in three patients receiving ICE after DexaBEAM failure, only one achieved an OR (1 PR). Median progression-free survival was significantly higher in the DexaBEAM group (6.4 vs. 2 months; P = 0.01). Major adverse event in both groups was myelosuppression with higher but tolerable treatment-related toxicity for patients in the DexaBEAM group. For all patients proceeding to HDT/ASCT, a 3-year overall survival was 50 %. Together, considering the limitations of the retrospective design of the evaluation and the small sample size, our data suggest that DexaBEAM salvage chemotherapy is superior to ICE for patients with relapsed or refractory aggressive PTCL for remission induction prior to autologous transplantation, with higher but manageable treatment-related toxicity.
KW - Adolescent
KW - Adult
KW - Aged
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Carboplatin
KW - Carmustine
KW - Combined Modality Therapy
KW - Cytarabine
KW - Dexamethasone
KW - Disease-Free Survival
KW - Drug Evaluation
KW - Etoposide
KW - Female
KW - Granulocyte Colony-Stimulating Factor
KW - Hematologic Diseases
KW - Hematopoietic Stem Cell Mobilization
KW - Humans
KW - Ifosfamide
KW - Kaplan-Meier Estimate
KW - Lymphoma, T-Cell, Peripheral
KW - Male
KW - Melphalan
KW - Middle Aged
KW - Mucositis
KW - Peripheral Blood Stem Cell Transplantation
KW - Preoperative Care
KW - Retrospective Studies
KW - Salvage Therapy
KW - Transplantation, Autologous
KW - Treatment Outcome
KW - Young Adult
U2 - 10.1007/s00277-013-1738-9
DO - 10.1007/s00277-013-1738-9
M3 - SCORING: Journal article
C2 - 23532626
VL - 92
SP - 1041
EP - 1048
JO - ANN HEMATOL
JF - ANN HEMATOL
SN - 0939-5555
IS - 8
ER -